Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016;16(1):5-13.
doi: 10.2174/1566523216666160119094143.

Building A New Treatment For Heart Failure-Transplantation of Induced Pluripotent Stem Cell-derived Cells into the Heart

Shigeru Miyagawa, Satsuki Fukushima, Yukiko Imanishi, Takuji Kawamura, Noriko Mochizuki-Oda, Shigeo Masuda, Yoshiki Sawa  1
Affiliations
Review

Building A New Treatment For Heart Failure-Transplantation of Induced Pluripotent Stem Cell-derived Cells into the Heart

Shigeru Miyagawa et al. Curr Gene Ther. 2016.

Abstract

Advanced cardiac failure is a progressive intractable disease and is the main cause of mortality and morbidity worldwide. Since this pathology is represented by a definite decrease in cardiomyocyte number, supplementation of functional cardiomyocytes into the heart would hypothetically be an ideal therapeutic option. Recently, unlimited in vitro production of human functional cardiomyocytes was established by using induced pluripotent stem cell (iPSC) technology, which avoids the use of human embryos. A number of basic studies including ours have shown that transplantation of iPSCderived cardiomyocytes (iPSC-CMs) into the damaged heart leads to recovery of cardiac function, thereby establishing "proof-of-concept" of this iPSC-transplantation therapy. However, considering clinical application of this therapy, its feasibility, safety, and therapeutic efficacy need to be further investigated in the pre-clinical stage. This review summarizes up-to-date important topics related to safety and efficacy of iPSC-CMs transplantation therapy for cardiac disease and discusses the prospects for this treatment in clinical studies.

PubMed Disclaimer

References

    1. Cohn J.N. Heart failure in 2013: Continue what we are doing to treat HF, but do it better. Nat. Rev. Cardiol. 2014;11(2):69–70. - PubMed
    1. Longnus S.L., Mathys V., Dornbierer M., et al. Heart transplantation with donation after circulatory determination of death. Nat. Rev. Cardiol. 2014;11(6):354–363. - PubMed
    1. Abraham W.T., Smith S.A. Devices in the management of advanced, chronic heart failure. Nat. Rev. Cardiol. 2013;10(2):98–110. - PMC - PubMed
    1. Koitabashi N., Kass D.A. Reverse remodeling in heart failure-mechanisms and therapeutic opportunities. Nat. Rev. Cardiol. 2012;9(3):147–157. - PubMed
    1. Saito S., Toda K., Miyagawa S., et al. Hemodynamic changes during left ventricular assist device-off test correlate with the degree of cardiac fibrosis and predict the outcome after device explantation. J. Artif. Organs. 2015;18(1):27–34. - PubMed

Publication types

MeSH terms